Allogene Therapeutics (ALLO) Interest Expenses (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Interest Expenses data on file, last reported at $102.7 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 629.38% year-over-year to $102.7 million; the trailing twelve-month figure through Mar 2026 stood at $102.7 million (up 629.38% YoY), and the FY2025 full-year result was $12.9 million, down 97.1% from the prior year.
• Interest Expenses improved to $102.7 million in Q1 2026, from $313000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $143.4 million in Q3 2022 to a low of -$6.0 million in Q4 2023.
• A 5-year average of $33.7 million and a median of $14.1 million in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses plunged 186.96% in 2023 and surged 629.38% in 2026, its largest moves.
• Tracing ALLO's Interest Expenses over 5 years: stood at $6.9 million in 2022, then plunged by 186.96% to -$6.0 million in 2023, then jumped by 101.35% to $81000.0 in 2024, then surged by 286.42% to $313000.0 in 2025, then jumped by 32708.31% to $102.7 million in 2026.
• Business Quant data shows ALLO's Interest Expenses at $102.7 million in Q1 2026, $313000.0 in Q4 2025, and $24.3 million in Q3 2025.